Localized Prostate Cancer VL

Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb

Details
Alicia Morgans is joined by Stacy Loeb to discuss her presentation at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on the risks and the benefits of active surveillance in the intermediate-risk population. Over the last several years, there has been an increase in the utilization of active surveillance in the United States for patients with intermediate r...

Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp

Details
The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...

The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss MARCAP, a meta-analysis of randomized trials in cancer of the prostate. This individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer in aggregate and in clinically releva...

Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain

Details
In this discussion, Paul Nguyen is joined by co-authors Bhav Jain and Edward Christopher Dee to discuss a Prostate Cancer and Prostatic Diseases publication "Racial Disparities in Treatment Delay Among Younger Men (<55 years of age) with Prostate Cancer". In this presentation and discussion, Bhav Jain shares that using the United States National Cancer Database (2004-2017), the authors' multivaria...

Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...

Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks

Details
Alicia Morgans and Michael Brooks discuss a recent manuscript entitled, “Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-years After Radical Prostatectomy”. Dr. Brooks goes into depth on how adverse pathology correlates with long-term prostate cancer outcomes. They also discuss active surveillance for low-risk patients and how to stratify th...

Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein

Details
Alicia Morgans and Eric Klein discuss two papers that involve a unique cohort of patients with early-stage prostate cancer. Dr. Klein details the use of the Oncotype GPS score to stratify patients and determine who is safe for active surveillance. They also discuss how to use MRI histology, adverse pathology, and genomic profiling systems together. They discuss advising clinicians on how to start...

AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt

Details
In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

Details
Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...

The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.

Details
Daniel Spratt and Randy Vince discuss the impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findings...
email news signup